12. PROTOCOL AMENDMENTS AND TERMINATION
If the protocol is amended, the investigators agreement with the amendment and the IRB/IEC approval of the amendment must be obtained.  Documentation acknowledging approval from both parties are to be submitted to the key sponsor contact. Both Kite Pharma and the investigator reserve the right to terminate the investigatorâ€™s participation in the study as per the terms of the agreement in the study contract.  The investigator is to provide written communication to the IRB/IEC of the trial completion or early termination and provide the CRO with a copy of the correspondence. Kite Pharma reserves the unilateral right, at is sole discretion, to determine whether to manufacture axicabtagene ciloleucel T cells and provide them to sites and subjects after the completion of the study and before treatment becomes commercially available.